{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:03:56Z","timestamp":1773907436974,"version":"3.50.1"},"reference-count":123,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MoST109-3114-Y-001-001"],"award-info":[{"award-number":["MoST109-3114-Y-001-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI129673"],"award-info":[{"award-number":["1R01AI129673"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    COVID-19 in humans is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that belongs to the beta family of coronaviruses. SARS-CoV-2 causes severe respiratory illness in 10\u201315% of infected individuals and mortality in 2\u20133%. Vaccines are urgently needed to prevent infection and to contain viral spread. Although several mRNA- and adenovirus-based vaccines are highly effective, their dependence on the \u201ccold chain\u201d transportation makes global vaccination a difficult task. In this context, a stable lyophilized vaccine may present certain advantages. Accordingly, establishing additional vaccine platforms remains vital to tackle SARS-CoV-2 and any future variants that may arise. Vaccinia virus (VACV) has been used to eradicate smallpox disease, and several attenuated viral strains with enhanced safety for human applications have been developed. We have generated two candidate SARS-CoV-2 vaccines based on two vaccinia viral strains, MVA and v-NY, that express full-length SARS-CoV-2 spike protein. Whereas MVA is growth-restricted in mammalian cells, the v-NY strain is replication-competent. We demonstrate that both candidate recombinant vaccines induce high titers of neutralizing antibodies in C57BL\/6 mice vaccinated according to prime-boost regimens. Furthermore, our vaccination regimens generated T\n                    <jats:sub>H<\/jats:sub>\n                    1-biased immune responses in mice. Most importantly, prime-boost vaccination of a Syrian hamster infection model with MVA-S and v-NY-S protected the hamsters against SARS-CoV-2 infection, supporting that these two vaccines are promising candidates for future development. Finally, our vaccination regimens generated neutralizing antibodies that partially cross-neutralized SARS-CoV-2 variants of concern.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0257191","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T14:13:14Z","timestamp":1631196794000},"page":"e0257191","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1603-4139","authenticated-orcid":true,"given":"Rakesh","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-9777","authenticated-orcid":true,"given":"Chi-Fei","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-7964","authenticated-orcid":true,"given":"Shiu-Lok","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Tsrong","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-4024","authenticated-orcid":true,"given":"Chun-Che","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0343-3720","authenticated-orcid":true,"given":"Jian-Jong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ying","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Pu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Shoiou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-4032","authenticated-orcid":true,"given":"Yu-Chiuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Chan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1838-6410","authenticated-orcid":true,"given":"Yi-Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-2307","authenticated-orcid":true,"given":"Che","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0783-1339","authenticated-orcid":true,"given":"Yu-Chi","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-083X","authenticated-orcid":true,"given":"Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"issue":"7798","key":"pone.0257191.ref001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"P Zhou","year":"2020","journal-title":"Nature"},{"issue":"4","key":"pone.0257191.ref002","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of V","year":"2020","journal-title":"Nat Microbiol"},{"issue":"20","key":"pone.0257191.ref003","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"C Drosten","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0257191.ref004","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"AM Zaki","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0257191.ref005","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","article-title":"Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics","volume":"20","author":"E Petersen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0257191.ref006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"JF Chan","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"pone.0257191.ref007","article-title":"Characteristics of SARS-CoV-2 and COVID-19","author":"B Hu","year":"2020","journal-title":"Nat Rev Microbiol"},{"issue":"21","key":"pone.0257191.ref008","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"J Shang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0257191.ref009","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","article-title":"Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor","volume":"11","author":"J Yang","year":"2020","journal-title":"Nat Commun"},{"issue":"7838","key":"pone.0257191.ref010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Z Ke","year":"2020","journal-title":"Nature"},{"issue":"2","key":"pone.0257191.ref011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"key":"pone.0257191.ref012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"L Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"7819","key":"pone.0257191.ref013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"B Ju","year":"2020","journal-title":"Nature"},{"key":"pone.0257191.ref014","first-page":"3541361","article-title":"Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions","volume":"2020","author":"A Grifoni","journal-title":"SSRN"},{"issue":"4","key":"pone.0257191.ref015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2","volume":"27","author":"A Grifoni","year":"2020","journal-title":"Cell Host Microbe."},{"issue":"5","key":"pone.0257191.ref016","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A Thermostable mRNA Vaccine against COVID-19","volume":"182","author":"NN Zhang","year":"2020","journal-title":"Cell"},{"issue":"7830","key":"pone.0257191.ref017","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"KS Corbett","year":"2020","journal-title":"Nature"},{"key":"pone.0257191.ref018","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","author":"AB Vogel","year":"2021","journal-title":"Nature"},{"issue":"7830","key":"pone.0257191.ref019","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"NB Mercado","year":"2020","journal-title":"Nature"},{"issue":"10255","key":"pone.0257191.ref020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"DY Logunov","year":"2020","journal-title":"Lancet"},{"issue":"7830","key":"pone.0257191.ref021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"N van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"pone.0257191.ref022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"F Krammer","year":"2020","journal-title":"Nature"},{"issue":"12","key":"pone.0257191.ref023","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe8065","article-title":"Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans","volume":"7","author":"PJ Klasse","year":"2021","journal-title":"Sci Adv"},{"key":"pone.0257191.ref024","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0257191.ref025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: Past, present, and future","volume":"118","author":"J Parrino","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"5\u20136","key":"pone.0257191.ref026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0147-9571(03)00025-0","article-title":"Smallpox vaccination and bioterrorism with pox viruses","volume":"26","author":"A Mayr","year":"2003","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"12","key":"pone.0257191.ref027","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"JH Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"pone.0257191.ref028","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","article-title":"Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination","volume":"30","author":"C Verheust","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"pone.0257191.ref029","doi-asserted-by":"crossref","first-page":"e0163164","DOI":"10.1371\/journal.pone.0163164","article-title":"DNA\/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus","volume":"11","author":"M Thompson","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"pone.0257191.ref030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.","volume":"20","author":"T Koch","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0257191.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"BL Jacobs","year":"2009","journal-title":"Antiviral Res"},{"issue":"8","key":"pone.0257191.ref032","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.11.79","article-title":"Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.","volume":"10","author":"SR Walsh","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"pone.0257191.ref033","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication","volume":"8","author":"PH Verardi","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"pone.0257191.ref034","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"J Heo","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"pone.0257191.ref035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity","volume":"23","author":"HJ Zeh","year":"2015","journal-title":"Mol Ther"},{"issue":"8","key":"pone.0257191.ref036","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers","volume":"24","author":"S Downs-Canner","year":"2016","journal-title":"Mol Ther"},{"issue":"18","key":"pone.0257191.ref037","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis","volume":"24","author":"UM Lauer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0257191.ref038","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"ZS Guo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0257191.ref039","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12967-019-2011-3","article-title":"First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells","volume":"17","author":"BR Minev","year":"2019","journal-title":"J Transl Med"},{"issue":"9","key":"pone.0257191.ref040","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/infdis\/jir527","article-title":"Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults","volume":"204","author":"JS Kennedy","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0257191.ref041","article-title":"COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice","author":"J Garcia-Arriaza","year":"2021","journal-title":"J Virol"},{"issue":"12","key":"pone.0257191.ref042","article-title":"One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection","volume":"118","author":"R Liu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0257191.ref043","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2021.02.001","article-title":"A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs","volume":"54","author":"NK Routhu","year":"2021","journal-title":"Immunity"},{"issue":"8741","key":"pone.0257191.ref044","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0140-6736(91)91636-9","article-title":"Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein","volume":"337","author":"EL Cooney","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"pone.0257191.ref045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/infdis\/166.2.244","article-title":"Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network","volume":"166","author":"BS Graham","year":"1992","journal-title":"J Infect Dis"},{"issue":"5","key":"pone.0257191.ref046","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.90.5.1882","article-title":"Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein","volume":"90","author":"EL Cooney","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0257191.ref047","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/167.3.533","article-title":"Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network","volume":"167","author":"BS Graham","year":"1993","journal-title":"J Infect Dis"},{"key":"pone.0257191.ref048","first-page":"195","article-title":"Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus","volume":"84","author":"G Sutter","year":"1995","journal-title":"Dev Biol Stand"},{"issue":"2","key":"pone.0257191.ref049","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice","volume":"212","author":"RM Martin","year":"1998","journal-title":"J Immunol Methods"},{"issue":"1","key":"pone.0257191.ref050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nri705","article-title":"TH1 and TH2 cells: a historical perspective","volume":"2","author":"FY Liew","year":"2002","journal-title":"Nature Reviews Immunology"},{"issue":"7","key":"pone.0257191.ref051","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"TR Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"pone.0257191.ref052","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.iy.12.040194.003223","article-title":"Acquisition of lymphokine-producing phenotype by CD4+ T cells","volume":"12","author":"RA Seder","year":"1994","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"pone.0257191.ref053","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.4049\/jimmunol.172.11.6533","article-title":"Cutting edge: effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung","volume":"172","author":"AD Roberts","year":"2004","journal-title":"J Immunol"},{"issue":"7818","key":"pone.0257191.ref054","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"SF Sia","year":"2020","journal-title":"Nature"},{"issue":"11","key":"pone.0257191.ref055","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"LH Tostanoski","year":"2020","journal-title":"Nat Med"},{"issue":"28","key":"pone.0257191.ref056","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"M Imai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0257191.ref057","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Y Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0257191.ref058","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1080\/22221751.2020.1858177","article-title":"Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection","volume":"9","author":"K Rosenke","year":"2020","journal-title":"Emerg Microbes Infec"},{"issue":"6520","key":"pone.0257191.ref059","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"A Baum","year":"2020","journal-title":"Science"},{"key":"pone.0257191.ref060","doi-asserted-by":"crossref","first-page":"618891","DOI":"10.3389\/fmicb.2020.618891","article-title":"SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters","volume":"11","author":"Z Song","year":"2020","journal-title":"Front Microbiol"},{"issue":"4","key":"pone.0257191.ref061","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/acschemneuro.0c00649","article-title":"Regeneration Profiles of Olfactory Epithelium after SARS-CoV-2 Infection in Golden Syrian Hamsters","volume":"12","author":"S Urata","year":"2021","journal-title":"ACS Chem Neurosci."},{"issue":"1","key":"pone.0257191.ref062","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"JS Driouich","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0257191.ref063","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-00279-z","article-title":"Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters","volume":"6","author":"RL Brocato","year":"2021","journal-title":"NPJ Vaccines."},{"issue":"2","key":"pone.0257191.ref064","doi-asserted-by":"crossref","first-page":"102054","DOI":"10.1016\/j.isci.2021.102054","article-title":"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model","volume":"24","author":"S Mohandas","year":"2021","journal-title":"iScience"},{"issue":"7830","key":"pone.0257191.ref065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"C Munoz-Fontela","year":"2020","journal-title":"Nature"},{"issue":"9","key":"pone.0257191.ref066","first-page":"2428","article-title":"Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility","volume":"71","author":"JF Chan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0257191.ref067","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.xcrm.2020.100121","article-title":"Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters","volume":"1","author":"AC Lee","year":"2020","journal-title":"Cell Rep Med"},{"key":"pone.0257191.ref068","first-page":"109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"2021","author":"TL Bricker","journal-title":"Cell Rep"},{"issue":"1","key":"pone.0257191.ref069","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/22221751.2021.1913974","article-title":"Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster","volume":"10","author":"M Brustolin","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"pone.0257191.ref070","doi-asserted-by":"crossref","DOI":"10.3390\/v12070779","article-title":"Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters","volume":"12","author":"N Osterrieder","year":"2020","journal-title":"Viruses."},{"issue":"10289","key":"pone.0257191.ref071","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data","volume":"397","author":"RH Shaw","year":"2021","journal-title":"Lancet"},{"issue":"7867","key":"pone.0257191.ref072","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/d41586-021-01805-2","article-title":"Mix-and-match COVID vaccines: the case is growing, but questions remain","volume":"595","author":"D Lewis","year":"2021","journal-title":"Nature"},{"issue":"7860","key":"pone.0257191.ref073","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41586-021-01359-3","article-title":"Mix-and-match COVID vaccines trigger potent immune response","volume":"593","author":"E Callaway","year":"2021","journal-title":"Nature"},{"key":"pone.0257191.ref074","article-title":"Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model","author":"S Dhakal","year":"2021","journal-title":"bioRxiv"},{"issue":"9","key":"pone.0257191.ref075","first-page":"2428","article-title":"Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility","volume":"71","author":"JFW Chan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0257191.ref076","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1148\/radiol.2020200230","article-title":"CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV).","volume":"295","author":"M Chung","year":"2020","journal-title":"Radiology."},{"issue":"8","key":"pone.0257191.ref077","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1007\/s00330-020-06801-0","article-title":"Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review","volume":"30","author":"Z Ye","year":"2020","journal-title":"Eur Radiol."},{"issue":"6494","key":"pone.0257191.ref078","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"J Shi","year":"2020","journal-title":"Science"},{"issue":"6494","key":"pone.0257191.ref079","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","volume":"368","author":"B Rockx","year":"2020","journal-title":"Science"},{"key":"pone.0257191.ref080","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","author":"TF Rogers","year":"2020","journal-title":"Science"},{"issue":"6","key":"pone.0257191.ref081","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10735-020-09915-3","article-title":"COVID-19 and multiorgan failure: A narrative review on potential mechanisms","volume":"51","author":"T Mokhtari","year":"2020","journal-title":"J Mol Histol."},{"issue":"8","key":"pone.0257191.ref082","doi-asserted-by":"crossref","first-page":"100618","DOI":"10.1016\/j.cpcardiol.2020.100618","article-title":"COVID-19 and Multiorgan Response","volume":"45","author":"S Zaim","year":"2020","journal-title":"Curr Probl Cardiol."},{"issue":"7","key":"pone.0257191.ref083","doi-asserted-by":"crossref","first-page":"e1009705","DOI":"10.1371\/journal.ppat.1009705","article-title":"SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney","volume":"17","author":"ME Francis","year":"2021","journal-title":"PLoS Pathog."},{"issue":"10262","key":"pone.0257191.ref084","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"GA Poland","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"pone.0257191.ref085","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"KS Corbett","year":"2020","journal-title":"N Engl J Med"},{"issue":"28","key":"pone.0257191.ref086","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"A Tscherne","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pone.0257191.ref087","first-page":"108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"AT Tan","journal-title":"Cell Rep. 2021"},{"issue":"25","key":"pone.0257191.ref088","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"EE Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"50","key":"pone.0257191.ref089","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"M Guebre-Xabier","year":"2020","journal-title":"Vaccine"},{"issue":"23","key":"pone.0257191.ref090","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: a selectable eukaryotic cloning and expression vector","volume":"79","author":"M Mackett","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0257191.ref091","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0076-6879(87)53077-4","article-title":"Vaccinia virus as an expression vector","volume":"153","author":"A Piccini","year":"1987","journal-title":"Methods Enzymol"},{"issue":"10249","key":"pone.0257191.ref092","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"PM Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"10267","key":"pone.0257191.ref093","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"MN Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"pone.0257191.ref094","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","author":"CL Hsieh","year":"2020","journal-title":"Science"},{"key":"pone.0257191.ref095","article-title":"Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model","author":"C Li","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0257191.ref096","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/jvi.62.1.176-180.1988","article-title":"Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97","volume":"62","author":"SL Hu","year":"1988","journal-title":"J Virol"},{"issue":"1","key":"pone.0257191.ref097","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"J Tartaglia","year":"1992","journal-title":"Virology"},{"issue":"18","key":"pone.0257191.ref098","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1073\/pnas.86.18.7213","article-title":"Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus","volume":"86","author":"SL Hu","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0257191.ref099","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/CVI.00597-15","article-title":"Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques","volume":"23","author":"R Thippeshappa","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"pone.0257191.ref100","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/jid.2013.418","article-title":"Langerin(+) Dermal DC, but Not Langerhans Cells, Are Required for Effective CD8-Mediated Immune Responses after Skin Scarification with Vaccinia Virus","volume":"134","author":"J Seneschal","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"31","key":"pone.0257191.ref101","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.vaccine.2017.05.058","article-title":"Comparative Efficacy of Intramuscular and Scarification Routes of Administration of Live Smallpox Vaccine in a Murine Challenge Model","volume":"35","author":"A Phelps","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"pone.0257191.ref102","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial.","volume":"21","author":"S Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pone.0257191.ref103","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","author":"R Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0257191.ref104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"New Engl J Med"},{"issue":"27","key":"pone.0257191.ref105","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0257191.ref106","article-title":"A thermostable mRNA vaccine against COVID-19","author":"N Zhang","year":"2020","journal-title":"Cell"},{"issue":"24","key":"pone.0257191.ref107","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"C Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"10269","key":"pone.0257191.ref108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"pone.0257191.ref109","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"L Feng","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0257191.ref110","article-title":"Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice","author":"RG King","year":"2020","journal-title":"bioRxiv"},{"issue":"4","key":"pone.0257191.ref111","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4049\/jimmunol.139.4.988","article-title":"Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins","volume":"139","author":"JM Zarling","year":"1987","journal-title":"J Immunol"},{"issue":"1","key":"pone.0257191.ref112","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0042-6822(90)90300-G","article-title":"Processing, Assembly, and Immunogenicity of Human-Immunodeficiency-Virus Core Antigens Expressed by Recombinant Vaccinia Virus","volume":"179","author":"SL Hu","year":"1990","journal-title":"Virology"},{"key":"pone.0257191.ref113","doi-asserted-by":"crossref","first-page":"14A 4 1","DOI":"10.1002\/9780471729259.mc14a04s39","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"39","author":"LS Wyatt","year":"2015","journal-title":"Curr Protoc Microbiol"},{"key":"pone.0257191.ref114","doi-asserted-by":"crossref","first-page":"14A 3 1","DOI":"10.1002\/9780471729259.mc14a03s39","article-title":"Preparation of Cell Cultures and Vaccinia Virus Stocks","volume":"39","author":"CA Cotter","year":"2015","journal-title":"Curr Protoc Microbiol"},{"issue":"12","key":"pone.0257191.ref115","first-page":"3403","article-title":"Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques","volume":"5","author":"S Chakrabarti","year":"1985","journal-title":"Mol Cell Biol"},{"issue":"24","key":"pone.0257191.ref116","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01600-17","article-title":"Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein","volume":"91","author":"SK Kasani","year":"2017","journal-title":"J Virol"},{"issue":"12","key":"pone.0257191.ref117","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1128\/JVI.06860-11","article-title":"Integrin beta1 mediates vaccinia virus entry through activation of PI3K\/Akt signaling","volume":"86","author":"R Izmailyan","year":"2012","journal-title":"J Virol"},{"issue":"9","key":"pone.0257191.ref118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/laban1005-39","article-title":"A rapid, simple, and humane method for submandibular bleeding of mice using a lancet","volume":"34","author":"WT Golde","year":"2005","journal-title":"Lab Animal"},{"issue":"5","key":"pone.0257191.ref119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177967","article-title":"The gingival vein as a minimally traumatic site for multiple blood sampling in guinea pigs and hamsters","volume":"12","author":"MV Rodrigues","year":"2017","journal-title":"Plos One"},{"issue":"1","key":"pone.0257191.ref120","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"TY Kuo","year":"2020","journal-title":"Sci Rep."},{"issue":"2","key":"pone.0257191.ref121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"MA Ramakrishnan","year":"2016","journal-title":"World J Virol"},{"key":"pone.0257191.ref122","doi-asserted-by":"crossref","first-page":"599587","DOI":"10.3389\/fimmu.2020.599587","article-title":"CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization","volume":"11","author":"BK Haun","year":"2020","journal-title":"Front Immunol."},{"issue":"3","key":"pone.0257191.ref123","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"VM Corman","year":"2020","journal-title":"Euro Surveill"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T17:39:08Z","timestamp":1673199548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257191"}},"subtitle":[],"editor":[{"given":"Zhilong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":123,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0257191","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.03.454910","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}